CVS Health Corporation (CVS)
CVS Health reported earnings that beat Wall Street's expectations and upgraded its projection for 2025, as its health-insurance business showed signs of recovery
The healthcare giant's results underscore a split among insurers between those that are struggling and those that are beginning to revive.
Is CVS Health (CVS) Stock Outpacing Its Medical Peers This Year?
Here is how CVS Health (CVS) and Agenus (AGEN) have performed compared to their sector so far this year.
CVS Health Care Delivery: Will the Growth Momentum Last in Q2?
CVS' Health Care Delivery unit posts strong growth from Signify and Oak Street, but rising medical costs pose a near-term risk.
Buy CVS Stock Ahead of Its Upcoming Earnings?
CVS Health (NYSE:CVS) is scheduled to announce its earnings on Thursday, July 31, 2025. For event-driven traders, analyzing the stock's historical behavior around earnings releases can provide valuable context.
Thousands of Americans are being forced to switch from Zepbound to Wegovy as a result of new coverage restrictions by CVS Caremark. ‘I just wish they would trust my doctor.
Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced better weight-loss results and fewer side effects.
Here's Why CVS Health (CVS) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
CVS Health (CVS) Stock Slides as Market Rises: Facts to Know Before You Trade
In the most recent trading session, CVS Health (CVS) closed at $58.75, indicating a -5.01% shift from the previous trading day.
CVS Health (CVS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
CVS Health (CVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
CVS Q2 Estimates Dip: Is the Stock Still a Buy Ahead of Q2 Earnings?
Earnings estimates for CVS dip ahead of Q2 results, but turnaround efforts in Aetna and PBM strength may offset pressure.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
What's Shaping CVS' Health Care Benefits Arm for the Rest of 2025?
CVS Health's Health Care Benefits arm posts solid Medicare gains and prepares for an ACA exit with a $448M reserve.
